On March 16, 2010, XOMA Ltd. announced that it has received a Staff Determination letter from The NASDAQ Stock Market LLC indicating that the company has not regained compliance with the minimum $1 per share requirement for continued inclusion on The NASDAQ Global Market, pursuant to NASDAQ Listing Rule 5450(a)(1) . As a result, the company's common shares would be subject to delisting from The NASDAQ Global Market unless XOMA requests a hearing before a NASDAQ Listing Qualifications Panel. Accordingly, XOMA intends to timely request a hearing before the Panel, which request will stay the delisting of the company's common shares pending the issuance of the Panel's decision following the hearing. At the hearing, XOMA intends to request continued listing on The NASDAQ Global Market based upon its plan for regaining compliance with the minimum bid price requirement. Pursuant to Listing Rule 5815(c), the Panel has the authority to grant XOMA up to an additional 180 days from the date of the Staff Determination letter of March 16, 2010 (i.e., until September 13, 2010) to implement its plan of compliance. As announced on September 21, 2009, XOMA received notice from NASDAQ that for the 30 consecutive business days preceding September 15, 2009, the bid price of its common shares closed below the minimum $1 per share required under Listing Rule 5450(a)(1). In accordance with Listing Rule 5810(c)(3)(A), XOMA had 180 calendar days, or until March 15, 2010, to regain compliance with this requirement.

XOMA Ltd. announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack). The results were presented at the American College of Cardiology 59th Annual Scientific Sessions in Atlanta. In the study, mice were randomly assigned to treatment with one of three doses of a murine equivalent of XOMA 052, a control antibody or saline immediately after surgery and again seven days later. Treatment with the two higher doses of XOMA 052 resulted in statistically significant improvements in measurements of left ventricular cardiac function including the ability to pump blood, which is related to an individual's chance of developing congestive heart failure. No signs of cardiac toxicity were observed. Following a heart attack, IL-1 beta is produced at the site of tissue injury and is responsible for endothelial activation, leukocyte recruitment, and amplification of the inflammatory response. In the context of myocardial infarction, IL-1 beta leads to further tissue damage, resulting in an enlargement and weakening of the heart ("cardiac remodeling"). A weaker heart cannot pump blood as efficiently, leading to congestive heart failure. The consequences of congestive heart failure include shortness of breath, reduced exertion capacity, edema (swelling), and changes in kidney function. People who have suffered a heart attack have substantially higher risk of developing congestive heart failure than those who have not had a heart attack. Approximately 5.7 million people in the U.S. have been diagnosed with congestive heart failure. Its incidence is increasing as survival following heart attack has increased (American Heart Association Statistical Update, 2009). XOMA 052 is a potent monoclonal antibody with the potential to improve the treatment of patients with a wide variety of inflammatory diseases. XOMA 052 binds strongly to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine involved in the development of Type 2 diabetes, cardiovascular disease, rheumatoid arthritis, gout and other diseases. By binding to IL-1 beta, XOMA 052 inhibits the activation of the IL-1 receptor, thereby preventing the cellular signaling events that produce inflammation. XOMA 052 has a half-life, binding properties and specificity for IL-1 beta that may provide for convenient dosing of once per month or less frequently.

XOMA Ltd. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2009. XOMA had total revenues of $98.4 million in 2009, compared with $68.0 million in 2008. XOMA had net income of $0.6 million, or $0.00 per basic and diluted share, in 2009 compared with a net loss of $45.2 million, or $0.34 per basic and diluted share, in the year ended 2008. In the year 2008, revenues included $16.4 million in license and collaborative fees, $30.5 million in contract and other revenue, and $21.1 million in royalties. For the quarter income from operations was $2.2 million against $11.6 million and net income before taxes was $2.6 million against $9.6 million reported last year. In the quarter ended December 31, 2009, XOMA had total revenues of $21.6 million and net income of $3.0 million, or $0.01 per basic and diluted share, compared with revenues of $36.9 million and net income of $10.0 million, or $0.07 per basic and diluted share in the fourth quarter of 2008. For the year income from operations was $13 million against loss from operations of $38.7 million and net income before taxes was $6.3 million against net loss before taxes of $45.6 million reported last year. The company will not be providing guidance on revenues or cash receipts for 2010 so as to best manage its ongoing negotiations for XOMA 052 and technology licensing and in light of general economic and market conditions. The company expects that cash used in operating activities to range from $45 million to cash neutral or positive.

XOMA Receives Anticipated Notice of Non-Compliance From NASDAQ

XOMA Ltd. Q4 2009 Earnings Call Transcript

XOMA Receives Anticipated Notice of Non-Compliance From NASDAQ

XOMA 052 Prevents Adverse Cardiac Remodeling in Animal Model of Heart Attack

XOMA 052 Phase 2 Trial Initiated in Type 1 Diabetes Patients

XOMA Reports 2009 and Fourth Quarter Financial Results

XOMA to Announce 2009 and Fourth Quarter Financial Results and Host Conference Call on March 11

Xoma 4Q profit falls as contract revenue tumbles

XOMA 052 Phase 2 Trial Initiated in Type 1 Diabetes Patients

XOMA 052 Prevents Adverse Cardiac Remodeling in Animal Model of Heart Attack

XOMA Reports 2009 and Fourth Quarter Financial Results

XOMA LTD /DE/ Files SEC form 10-K, Annual Report

XOMA to Announce 2009 and Fourth Quarter Financial Results and Host Conference Call on March 11

Xoma offering $21 million in stock and warrants

Liberty Analytics Co. Initiates Independent Research Coverage on XOMA Ltd.

XOMA to Webcast Presentations From Two March 2010 Investment Conferences

XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients

XOMA Announces Presentation at BIO CEO and Investor Conference on February 9

Xoma offering $21 million in stock and warrants

XOMA to Webcast Presentations From Two March 2010 Investment Conferences